Everence Capital Management Inc Cytek Biosciences, Inc. Transaction History
Everence Capital Management Inc
- $1.59 Billion
- Q3 2024
A detailed history of Everence Capital Management Inc transactions in Cytek Biosciences, Inc. stock. As of the latest transaction made, Everence Capital Management Inc holds 16,760 shares of CTKB stock, worth $102,738. This represents 0.01% of its overall portfolio holdings.
Number of Shares
16,760
Previous 13,860
20.92%
Holding current value
$102,738
Previous $83,000
12.05%
% of portfolio
0.01%
Previous 0.01%
Shares
3 transactions
Others Institutions Holding CTKB
# of Institutions
135Shares Held
72.2MCall Options Held
400Put Options Held
0-
Black Rock Inc. New York, NY17.1MShares$105 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.8MShares$72.2 Million0.0% of portfolio
-
Brown Capital Management LLC Baltimore, MD9.49MShares$58.2 Million1.15% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E96.66MShares$40.8 Million0.85% of portfolio
-
State Street Corp Boston, MA4.17MShares$25.5 Million0.0% of portfolio
About Cytek Biosciences, Inc.
- Ticker CTKB
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 134,627,008
- Market Cap $825M
- Description
- Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers ...